NDAORALTABLETPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 28m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOCABRIA (cabotegravir sodium) is an oral small-molecule integrase strand transfer inhibitor (INSTI) approved by the FDA in January 2021 for HIV-1 treatment. It is designed as a component of combination antiretroviral therapy for treatment-experienced adults with HIV-1 infection resistant to multiple antiretroviral drug classes. The drug works by inhibiting HIV integrase, an enzyme critical to viral replication.
Peak4.6 years to LOE
Product is at peak commercial maturity with established market presence; brand teams are likely focused on market maintenance and defending against competitive incursions rather than primary launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOCABRIA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.